NTHI Stock Summary and Trading Ideas (Neonc Technologies Hldgs | NASDAQ:NTHI)

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Neonc Technologies Hldgs trades on the NASDAQ stock market under the symbol NTHI.

As of September 14, 2026, NTHI stock price climbed to $3.78 with 278,177 million shares trading.

NTHI has a beta of 2.98, meaning it tends to be more sensitive to market movements. NTHI has a correlation of 0.10 to the broad based SPY ETF.

NTHI has a market cap of $108.88 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that NTHI belongs to (by Net Assets): VTI, VXF, IWC, BUSM.

NTHI has underperformed the market in the last year with a price return of -61.3% while the SPY ETF gained +16.8%. NTHI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.0% and -19.4%, respectively, while the SPY returned +3.4% and -1.1%, respectively.

NTHI support price is $3.33 and resistance is $4.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTHI shares will trade within this expected range on the day.